Maravai LifeSciences Holdings Management
Management criteria checks 1/4
Maravai LifeSciences Holdings' CEO is Trey Martin, appointed in Jul 2023, has a tenure of less than a year. total yearly compensation is $14.52M, comprised of 4.5% salary and 95.5% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth MX$18.99M. The average tenure of the management team and the board of directors is 1.3 years and 3.3 years respectively.
Key information
Trey Martin
Chief executive officer
US$14.5m
Total compensation
| CEO salary percentage | 4.5% |
| CEO tenure | less than a year |
| CEO ownership | 0.05% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$119m |
| Sep 30 2023 | n/a | n/a | US$25m |
| Jun 30 2023 | n/a | n/a | US$75m |
| Mar 31 2023 | n/a | n/a | US$153m |
| Dec 31 2022 | US$15m | US$660k | US$220m |
Compensation vs Market: Trey's total compensation ($USD14.52M) is above average for companies of similar size in the MX market ($USD756.62K).
Compensation vs Earnings: Insufficient data to compare Trey's compensation with company performance.
CEO
Trey Martin (48 yo)
less than a year
Tenure
US$14,523,493
Compensation
Mr. William E. Martin, III, also known as Trey, was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. since December 5, 2022 until July 27, 2023 and is Chief Executive Officer fr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.3yrs | US$5.48m | 0.052% MX$ 18.8m | |
| Chief Executive Officer | less than a year | US$14.52m | 0.053% MX$ 19.0m | |
| Executive VP & CFO | 6.8yrs | US$1.74m | 0.0093% MX$ 3.3m | |
| Executive VP & Chief Administrative Officer | 1.7yrs | US$3.92m | 0.014% MX$ 4.9m | |
| Executive Vice President of Biologics Safety Testing | 6.3yrs | US$1.59m | 0.0093% MX$ 3.4m | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive VP | 3.3yrs | US$701.40k | 0.013% MX$ 4.6m | |
| Executive VP & Chief Commercial Officer | 1yr | no data | 0.0074% MX$ 2.7m | |
| Chief Innovation Officer | 1yr | no data | no data | |
| Executive Vice President of Enzymes | 1yr | no data | no data | |
| President of Nucleic Acid Production | less than a year | no data | no data |
1.3yrs
Average Tenure
53yo
Average Age
Experienced Management: MRVI *'s management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.3yrs | US$5.48m | 0.052% MX$ 18.8m | |
| Director | less than a year | no data | no data | |
| Non-Independent Director | 3.3yrs | US$66.25k | 0.0032% MX$ 1.2m | |
| Non-Independent Director | 3.3yrs | US$46.88k | 0.0032% MX$ 1.2m | |
| Independent Director | 3.3yrs | US$45.00k | 0.021% MX$ 7.4m | |
| Independent Director | 3.3yrs | US$68.75k | 0.024% MX$ 8.8m | |
| Non-Independent Director | 3.3yrs | US$54.38k | 0.0032% MX$ 1.2m | |
| Non-Independent Director | 3.3yrs | US$45.00k | 0.0032% MX$ 1.2m | |
| Independent Director | 3.3yrs | US$46.88k | 0.013% MX$ 4.6m | |
| Independent Director | 3.3yrs | US$68.75k | 0.047% MX$ 16.9m | |
| Independent Director | 3.3yrs | US$60.63k | 0.0092% MX$ 3.3m |
3.3yrs
Average Tenure
58yo
Average Age
Experienced Board: MRVI *'s board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/25 14:49 |
| End of Day Share Price | 2023/11/28 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |